IXICO signs new contract to deploy biosensors in a Phase II neurological clinical trial

IXICO today announces that it has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors (‘wearable biosensors’) in a Phase II clinical trial for a neurological disorder.

This is IXICO’s first commercial agreement using activity sensors to evaluate exploratory digital measures in early phase clinical research and follows a presentation of IXICO’s approach to measuring sleep disturbances at the “Mobile devices for clinical trials in neurological diseases workshop” earlier this year at the Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute Coalition Against Major Diseases (CAMD) meetings.

By |2017-10-10T15:06:16+00:004 October 2017|Contracts|